Skip to main content

39 - References

References

Prescribing in children and adolescents CHAPTER 5 References

  1. Lai MC, et  al. Prevalence of co-­occurring mental health diagnoses in the autism population: a systematic review and meta-­analysis. Lancet Psychiatry 2019; 6:­819–­829.
  2. Lever AG, et al. Psychiatric co-­occurring symptoms and disorders in young, middle-­aged, and older adults with autism spectrum disorder. J Autism Dev Disord 2016; 46:­1916–­1930.
  3. Buck TR, et  al. Psychiatric comorbidity and medication use in adults with autism spectrum disorder. J Autism Dev Disord 2014; 44:­3063–­3071.
  4. Goel R, et al. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. Int Rev Psychiatry 2018; 30:­78–­95.
  5. Accordino RE, et al. Psychopharmacological interventions in autism spectrum disorder. Expert Opin Pharmacother 2016; 17:­937–­952.
  6. Howes OD, et al. Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. J Psychopharmacol 2018; 32:­3–­29.
  7. Santosh P. Medication in autism spectrum disorder. Cut Edge Psychiatry Pract 2014; 1:­143–­155.
  8. Greenhill LL. Assessment of safety in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2003; 42:­625–­626.
  9. Leekam SR, et al. Restricted and repetitive behaviors in autism spectrum disorders: a review of research in the last decade. Psychol Bull 2011; 137:­562–­593.
  10. Williams K, et al. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2013; 8:CD004677.
  11. Liang SC, et al. Therapeutic effects of antidepressants for global improvement and subdomain symptoms of autism spectrum disorder: a systematic review and meta-­analysis. J Psychiatry Neurosci 2022; 47:­e299–­e310.
  12. McDougle CJ, et al. A double-­blind, placebo-­controlled study of risperidone addition in serotonin reuptake inhibitor-­refractory obsessive-­ compulsive disorder. Arch Gen Psychiatry 2000; 57:­794–­801.
  13. McDougle CJ, et al. Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. Am J Psychiatry 2005; 162:­1142–­1148.
  14. McCracken JT, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347:­314–­321.
  15. Arnold LE, et al. Parent-­defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 2003; 42:­1443–­1450.
  16. Dinnissen M, et al. Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder. Expert Opin Drug Metab Toxicol 2015; 11:­111–­124.
  17. Zhou MS, et al. Meta-­analysis: pharmacologic treatment of restricted and repetitive behaviors in autism spectrum disorders. J Am Acad Child Adolesc Psychiatry 2020; 60:­35–­45.
  18. Yu Y, et  al. Pharmacotherapy of restricted/repetitive behavior in autism spectrum disorder: a systematic review and meta-­analysis. BMC Psychiatry 2020; 20:121.
  19. Canitano R, et al. Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents. Neuropsychiatr Dis Treat 2008; 4:­723–­730.
  20. Scahill L, et al. Brief report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. J Autism Dev Disord 2013; 43:­739–­746.
  21. Posey DJ, et al. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am 2008; 17:­787–­801.
  22. Ooi YP, et  al. Oxytocin and autism spectrum disorders: a systematic review and meta-­analysis of randomized controlled trials. Pharmacopsychiatry 2017; 50:­5–­13.
  23. Hu L, et al. Oxytocin treatment for core symptoms in children with autism spectrum disorder: a systematic review and meta-­analysis. Eur J Clin Pharmacol 2023; 79:­1357–­1363.
  24. Guastella AJ, et al. The effect of oxytocin nasal spray on social interaction in young children with autism: a randomized clinical trial. Mol Psychiatry 2023; 28:­834–­842.
  25. Sikich L, et al. Intranasal oxytocin in children and adolescents with autism spectrum disorder. N Engl J Med 2021; 385:­1462–­1473.
  26. Alvares GA, et al. Beyond the hype and hope: critical considerations for intranasal oxytocin research in autism spectrum disorder. Autism Res 2017; 10:­25–­41.
  27. McGuinness G, et al. Sulforaphane treatment for autism spectrum disorder: a systematic review. EXCLI J 2020; 19:­892–­903.
  28. Magner M, et al. Sulforaphane treatment in children with autism: a prospective randomized double-­blind study. Nutrients 2023; 15:718.
  29. Zimmerman AW, et al. Randomized controlled trial of sulforaphane and metabolite discovery in children with autism spectrum disorder. Mol Autism 2021; 12:38.
  30. Riikonen R. Treatment of autistic spectrum disorder with insulin-­like growth factors. Eur J Paediatr Neurol 2016; 20:­816–­823.
  31. Fung LK, et al. Developing medications targeting glutamatergic dysfunction in autism: progress to date. CNS Drugs 2015; 29:­453–­463.
  32. Aye SZ, et al. The effectiveness and adverse effects of D-­cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder. Cochrane Database Syst Rev 2021; 2:CD013457.
  33. Brignell A, et al. Memantine for autism spectrum disorder. Cochrane Database Syst Rev 2022; 8:CD013845.
  34. Dean OM, et al. A randomised, double blind, placebo-­controlled trial of a fixed dose of N-­acetyl cysteine in children with autistic disorder. Aust N Z J Psychiatry 2017; 51:­241–­249.
  35. Thom RP, et al. Recent updates in psychopharmacology for the core and associated symptoms of autism spectrum disorder. Curr Psychiatry Rep 2021; 23:79.
  36. Sathe N, et al. Nutritional and dietary interventions for autism spectrum disorder: a systematic review. Pediatrics 2017; 139:e20170346.

612 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 5 37. Peretti S, et al. Diet: the keystone of autism spectrum disorder? Nutr Neurosci 2019; 22:­825–­839. 38. Yang Y, et al. Targeting gut microbiome: a novel and potential therapy for autism. Life Sci 2018; 194:­111–­119. 39. Lee YJ, et al. Advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder. Clin Psychopharmacol Neurosci 2014; 12:­19–­30. 40. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005; 62:­1266–­1274. 41. Posey DJ, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry 2007; 61:­538–­544. 42. Santosh PJ, et al. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity ­disorder: a retrospective and prospective effectiveness study. Child Care Health Dev 2006; 32:­575–­583. 43. Simonoff E, et al. Randomized controlled double-­blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. J Child Psychol Psychiatry 2013; 54:­527–­535. 44. Sung M, et al. What’s in the pipeline? Drugs in development for autism spectrum disorder. Neuropsychiatr Dis Treat 2014; 10:­371–­381. 45. Siegel M, et al. Psychotropic medications in children with autism spectrum disorders: a systematic review and synthesis for evidence-­based practice. J Autism Dev Disord 2012; 42:­1592–­1605. 46. Williamson ED, et al. Psychotropic medications in autism: practical considerations for parents. J Autism Dev Disord 2012; 42:­1249–­1255. 47. Rodrigues R, et al. Practitioner review: pharmacological treatment of attention-­deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-­analysis. J Child Psychol Psychiatry 2021; 62:­680–­700. 48. Coghill D, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-­deficit/ hyperactivity disorder. Eur Neuropsychopharmacol 2013; 23:­1208–­1218. 49. Arnold LE, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-­controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006; 45:­1196–­1205. 50. Harfterkamp M, et al. A randomized double-­blind study of atomoxetine versus placebo for attention-­deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2012; 51:­733–­741. 51. Handen BL, et al. Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-­deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2015; 54:­905–­915. 52. Smith T, et al. Atomoxetine and parent training for children with autism and attention-­deficit/hyperactivity disorder: a 24-­week extension study. J Am Acad Child Adolesc Psychiatry 2016; 55:­868–­876.e862. 53. Scahill L, et  al. Extended-­release guanfacine for hyperactivity in children with autism spectrum disorder. Am J Psychiatry 2015; 172:­1197–­1206. 54. National Institute for Health and Care Excellence. Autism spectrum disorder in under 19s: support and management. Clinical Guidance 170 [CG170]. 2013 (last updated June 2021, last checked February 2024); https://www.nice.org.uk/guidance/CG170. 55. Kaplan G, et al. Psychopharmacology of autism spectrum disorders. Pediatr Clin North Am 2012; 59:­175–­187, xii. 56. McDougle CJ, et al. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 2008; 69 Suppl 4:­15–­20. 57. Parikh MS, et al. Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol 2008; 18:­157–­178. 58. DeVane CL, et al. Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacotherapy 2019; 39:­626–­635. 59. Jesner OS, et al. Risperidone for autism spectrum disorder. Cochrane Database Syst Rev 2007; 2007:CD005040. 60. Scahill L, et al. Risperidone approved for the treatment of serious behavioral problems in children with autism. J Child Adolesc Psychiatr Nurs 2007; 20:­188–­190. 61. Curran MP. Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients. PaediatrDrugs 2011; 13:­197–­204. 62. Fung LK, et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-­analysis. Pediatrics 2016; 137 Suppl 2:­S124–­S135. 63. Douglas-­Hall P, et al. Aripiprazole: a review of its use in the treatment of irritability associated with autistic disorder patients aged 6-­17. J Cent Nerv Syst Dis 2011; 3:­1–­11. 64. Iffland M, et  al. Pharmacological intervention for irritability, aggression, and self-­injury in autism spectrum disorder (ASD). Cochrane Database Syst Rev 2023; 10:CD011769. 65. Caccia S. Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Paediatr Drugs 2013; 15:­217–­233. 66. Sharma A, et al. Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-­analysis. J Pediatr Health Care 2012; 26:­291–­299. 67. Kent JM, et al. Risperidone dosing in children and adolescents with autistic disorder: a double-­blind, placebo-­controlled study. J Autism Dev Disord 2013; 43:­1773–­1783. 68. Maayan L, et al. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2011; 21:­517–­535. 69. Hermans RA, et al. The effect of therapeutic drug monitoring of risperidone and aripiprazole on weight gain in children and adolescents: the SPACe 2: STAR (trial) protocol of an international multicentre randomised controlled trial. BMC Psychiatry 2022; 22:814. 70. Hirsch LE, et al. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2016; 2016:CD009043. 71. Ghanizadeh A, et al. A head-­to-­head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev 2014; 45:­185–­192.

Prescribing in children and adolescents CHAPTER 5 72. Loebel A, et al. Lurasidone for the treatment of irritability associated with autistic disorder. J Autism Dev Disord 2016; 46:­1153–­1163. 73. Hollander E, et al. A double-­blind placebo-­controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006; 16:­541–­548. 74. Campbell M, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-­blind and placebo-­controlled study. J Am Acad Child Adolesc Psychiatry 1995; 34:­445–­453. 75. Malone RP, et al. A double-­blind placebo-­controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 2000; 57:­649–­654. 76. Donovan SJ, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-­blind, placebo-­controlled crossover design. Am J Psychiatry 2000; 157:­818–­820. 77. Stigler KA, et  al. Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatr Clin N Am 2008; 17:­739–­752. 78. Rezaei V, et  al. Double-­blind, placebo-­controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:­1269–­1272. 79. Hellings JA, et al. Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline. Expert Opin Pharmacother 2017; 18:­581–­588. 80. Janssen Pharmaceutical Companies. Highlights of prescribing information. Risperdal® (risperidone) tablets, for oral use, Risperdal® (­risperidone) oral solution, Risperdal® M-­TAB® (risperidone) orally disintegrating tablets. 2019; https://www.accessdata.fda.gov/­drugsatfda_ docs/label/2019/020272s082,020588s070,021444s056lbl.pdf. 81. Krakowiak P, et al. Sleep problems in children with autism spectrum disorders, developmental delays, and typical development: a population-­ based study. J Sleep Res 2008; 17:­197–­206. 82. Sanchez-­Barcelo EJ, et al. Clinical uses of melatonin in pediatrics. Int J Pediatr 2011; 2011:892624. 83. Doyen C, et al. Melatonin in children with autistic spectrum disorders: recent and practical data. Eur Child Adolesc Psychiatry 2011; 20:­231–­239. 84. Rossignol DA, et  al. Melatonin in autism spectrum disorders: a systematic review and meta-­analysis. Dev Med Child Neurol 2011; 53:­783–­792. 85. Andersen IM, et al. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol 2008; 23:­482–­485. 86. Gringras P, et al. Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo ­controlled trial. BMJ 2012; 345:e6664. 87. Cortesi F, et al. Controlled-­release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-­controlled trial. J Sleep Res 2012; 21:­700–­709. 88. Johnson KP, et al. Sleep in children with autism spectrum disorders. Curr Treat Options Neurol 2008; 10:­350–­359. 89. Reddihough DS, et al. Effect of fluoxetine on obsessive-­compulsive behaviors in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA 2019; 322:­1561–­1569. 90. Buitelaar JK, et al. Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-­label study. J Clin Psychiatry 1998; 59:­56–­59. 91. Narayanan A, et al. Effect of propranolol on functional connectivity in autism spectrum ­disorder –­ a pilot study. Brain Imaging Behav 2010; 4:­189–­197.

No comments to display

Back to top